Open AccessRecent Advances in Mode of Action and Biosynthesis Studies of the Clinically Used Antibiotic Fidaxomicin
Author(s) -
Andrea Dorst,
Erik Jung,
Karl Gademann
Publication year - 2020
Publication title -
chimia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 55
eISSN - 2673-2424
pISSN - 0009-4293
DOI - 10.2533/chimia.2020.270
Subject(s) - fidaxomicin , mycobacterium tuberculosis , mode of action , antibiotics , natural product , microbiology and biotechnology , drug development , drug , biology , computational biology , chemistry , medicine , tuberculosis , pharmacology , biochemistry , bacteria , vancomycin , pathology , genetics , staphylococcus aureus
The natural product antibiotic fidaxomicin is a marketed drug for the treatment of bacterial infections in the gut. Due to its promising in vitro activities against Mycobacterium tuberculosis, the development of next generation fidaxomicin analogs is of great interest. This article reviews the most recent advances, including the elucidation of a unique mode of action by cryo-EM structures, and the efforts towards the clarification of the biosynthetic pathway. Moreover, known fidaxomicin analogs and their reported antibacterial activities are summarized.